Landmark CRISPR approval; Why don’t investors like Verve’s base editing data?; Janet Woodcock to retire; Late Friday IPO filing; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

This week, we show­case End­points’ on-the-ground cov­er­age with dis­patch­es from the AHA meet­ing in Philadel­phia and the Jef­feries con­fer­ence in Lon­don. But don’t miss the string of new ap­provals, deals, fi­nanc­ing and de­par­tures, ei­ther.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.